You are now leaving the pages of www.gilead.com intended for U.S. audiences. The information in this section is intended for visitors outside the United States.
U.S. FDA Accepts New Drug Application for Gilead’s Once-Daily, Single-Tablet Quad HIV Regimen
Gilead Files European Marketing Application for the Quad, a Once-Daily Single-Tablet Regimen for the Treatment of HIV Infection
Gilead Sciences Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Truvada® for Reducing the Risk of Acquiring HIV
Gilead Announces Two-Year Data From Pivotal Phase 3 Study of Elvitegravir, an Integrase Inhibitor for HIV
Gilead Sciences and World Health Organization Establish New Five-Year Initiative to Prevent Deaths from Visceral Leishmaniasis
Gilead Prices $3.7 Billion of Senior Unsecured Notes
Gilead’s Boosting Agent, Cobicistat, Meets 48-Week Primary Objective in Pivotal Phase 3 Study
Gilead Sciences to Present at the 23rd Annual Piper Jaffray Healthcare Conference on Tuesday, November 29
Gilead Receives European Marketing Authorization for Eviplera(R), a New Complete Once-Daily, Single-Tablet Regimen for HIV-1 Infection in Treatment-Naive Adults
Gilead Sciences to Acquire Pharmasset, Inc. for $11 Billion
Gilead Sciences Finalizes Agreement with Tibotec Pharmaceuticals to Develop and Commercialize a Single-Tablet Regimen of Prezista(R) with Emtriva(R), GS 7340 and Cobicistat
Gilead Sciences to Present at the Lazard Capital Markets 8th Annual Healthcare Conference on Tuesday, November 15
Gilead Sciences to Present at the 2011 Credit Suisse Healthcare Conference on Wednesday, November 9
Gilead Sciences and Cardiovascular Research Foundation Initiate Phase 3 Clinical Trial with Ranolazine in Patients Who Have Undergone PCI with a History of Prior Chronic Angina
Gilead Announces Positive Five-Year Data Showing Effect of Viread(R) on Liver Fibrosis and Cirrhosis Caused by Chronic Hepatitis B
Gilead Sciences Announces Third Quarter 2011 Financial Results
Gilead Submits New Drug Application to U.S. FDA for Once-Daily, Single-Tablet "Quad" HIV Regimen
Bristol-Myers Squibb and Gilead Sciences Announce Licensing Agreement for Development and Commercialization of New Fixed-Dose Combination Pill for People Living with HIV
Gilead and GlobeImmune Announce License and Collaboration Agreement to Develop Therapeutic Vaccine Products for Treatment of Chronic Hepatitis B Infection
Gilead Sciences to Release Third Quarter 2011 Financial Results on Thursday, October 27, 2011
Gilead and Boehringer Ingelheim Sign License Agreement for Novel HIV Non-Catalytic Integrase Inhibitors
European CHMP Adopts Positive Opinion for Eviplera(R), a Once-Daily Single-Tablet Regimen for the Treatment of HIV Infection
Gilead Sciences to Present at the UBS Global Life Sciences Conference on Tuesday, September 20
Gilead's Second Pivotal Phase 3 Clinical Study of the Investigational Antiretroviral Quad Regimen Meets 48-Week Primary Objective
Gilead Amends Study Design for Ongoing Hepatitis C Clinical Trials That Include GS 9190, Pegylated Interferon and Ribavirin, and Another Direct-Acting Antiviral Agent
Gilead Sciences to Present at Baird's 2011 Health Care Conference on Thursday, September 8
Gilead's Investigational Antiretroviral Quad Regimen Meets 48-Week Primary Objective in Pivotal Phase 3 Clinical Study 102
Gilead Sciences Resolves U.S. Food and Drug Administration Warning Letter Related to San Dimas Manufacturing Facility
U.S. Food and Drug Administration Approves Gilead Sciences' Complera(TM), a New Complete Once-Daily, Single-Tablet Regimen for HIV-1 Infection in Treatment-Naïve Adults
Gilead Sciences to Purchase Biologics Process Research and Clinical Manufacturing Facility from Genentech
Gilead Sciences Announces Second Quarter 2011 Financial Results
Gilead's Investigational Antiretroviral Elvitegravir Once Daily Non-Inferior to Raltegravir Twice Daily at 48 Weeks
Gilead Sciences to Release Second Quarter 2011 Financial Results on Tuesday, July 26, 2011
Gilead Expands Access Program for Medications in Developing World
Gilead Sciences Announces Agreement With Tibotec Pharmaceuticals to Develop and Commercialize a New Fixed-Dose Combination of Cobicistat and Prezista(R)
Gilead Sciences to Present at Two Upcoming Investor Conferences
Gilead Sciences' Executive Vice President Kevin Young Appointed a Commander of the Most Excellent Order of the British Empire
Gilead Sciences Receives Subpoena from U.S. Department of Justice
Gilead Sciences to Present at the 31st Annual William Blair & Company Growth Stock Conference on Wednesday, June 15
Gilead Extends Its Funding Support for the Gilead Sciences Research Centre at the Institute of Organic Chemistry and Biochemistry in Prague
Gilead Sciences to Present at the Deutsche Bank 36th Annual Health Care Conference on Tuesday, May 3
Gilead Appoints Dr. Muzammil M. Mansuri as Senior Vice President, Research and Development Strategy and Corporate Development
Gilead Sciences Announces First Quarter 2011 Financial Results
Gilead and MicroDose Therapeutx Announce License and Collaboration Agreement to Develop MDT-637 for Treatment of Respiratory Syncytial Virus
Gilead Sciences to Release First Quarter 2011 Financial Results on Wednesday, April 20, 2011
Yale and Gilead Sciences Announce Cancer Research Collaboration
Gilead Prices $1 Billion of Senior Unsecured Notes
Gilead to Offer Senior Notes
Phase III Clinical Trial of Gilead's Investigational Elvitegravir Meets 48-Week Primary Objective
Gilead Recommends Rejection of Mini-Tender Offer By TRC Capital Corporation
U.S. FDA Removes Warning about Potential Liver Injury from Boxed Warning of Prescribing Information for Gilead's Letairis
Gilead Sciences to Present at the Cowen & Company 31st Annual Health Care Conference on Monday, March 7
Gilead Sciences to Acquire Calistoga Pharmaceuticals for $375 Million
Gilead Sciences Refiles New Drug Application with the FDA for Single-Tablet Regimen of Truvada(R) and TMC278
Gilead Sciences Announces Notification of ANDA Filing for Tamiflu(R)
Gilead Sciences Announces Fourth Quarter and Full Year 2010 Financial Results
Gilead Sciences Receives Refuse to File Notification From U.S. FDA on New Drug Application for Single-Tablet Regimen of Truvada(R) and TMC278
Gilead Sciences to Release Fourth Quarter and Year End 2010 Financial Results on Tuesday, January 25, 2011
Gilead Sciences to Present at the 29th Annual JPMorgan Healthcare Conference on Monday, January 10
2012 Interactive Annual Report